631 related articles for article (PubMed ID: 15093806)
1. Calcineurin inhibitors in heart transplantation.
Keogh A
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
[TBL] [Abstract][Full Text] [Related]
2. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Valantine H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitors in heart transplantation.
Crespo-Leiro MG
Transplant Proc; 2005 Nov; 37(9):4018-20. PubMed ID: 16386614
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
5. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
[TBL] [Abstract][Full Text] [Related]
6. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
7. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
Reichenspurner H
J Heart Lung Transplant; 2005 Feb; 24(2):119-30. PubMed ID: 15701425
[TBL] [Abstract][Full Text] [Related]
8. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
11. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
12. Cardiac transplant experience with cyclosporine.
Patel JK; Kobashigawa JA
Transplant Proc; 2004 Mar; 36(2 Suppl):323S-330S. PubMed ID: 15041362
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus.
Maes BD; Vanrenterghem YF
Transplant Proc; 2004 Mar; 36(2 Suppl):40S-49S. PubMed ID: 15041305
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis.
Ye F; Ying-Bin X; Yu-Guo W; Hetzer R
J Heart Lung Transplant; 2009 Jan; 28(1):58-66. PubMed ID: 19134532
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus based immunosuppression.
First MR
J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
[TBL] [Abstract][Full Text] [Related]
17. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
18. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Jardine AG
Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
[TBL] [Abstract][Full Text] [Related]
19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
Vincenti F; Rostaing L;
Contemp Clin Trials; 2005 Feb; 26(1):17-24. PubMed ID: 15837449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
